FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2760380650> ?p ?o ?g. }

• W2760380650 endingPage "6237" @default.
• W2760380650 startingPage "6228" @default.
• W2760380650 abstract "Rotavirus is the most common cause of moderate-to-severe infant diarrhoea in developing countries, resulting in enormous morbidity, mortality, and economic burden. A bovine-human reassortant pentavalent rotavirus vaccine (BRV-PV) targeting the globally most common strains was developed in India and tested in a randomized, double-blind, placebo-controlled end-point driven Phase III efficacy clinical trial implemented at six sites across India. Infants 6 to 8weeks of age were randomized (1:1) to receive three oral doses of BRV-PV or placebo at 6, 10, and 14weeks of age along with routine vaccines. Home visit surveillance was conducted to detect severe rotavirus gastroenteritis (SRVGE) and safety outcomes until the children reached two years of age. A total of 3749 infants received BRV-PV while 3751 received placebo. At the time of the primary end-point (when the minimum number of cases needed for analysis were accrued) the vaccine efficacy against SRVGE was 36% (95% CI 11.7, 53.6, p=0.0067) in the per protocol (PP) analysis, and 41.9% (95% CI 21.1, 57.3, p=0.0005) in the intent to treat (ITT) analysis. Vaccine efficacy over the entire follow-up period (until children reached two years of age) was 39.5% (95% CI 26.7, 50, p<0.0001) in the PP analysis and 38.8% (95% CI, 26.4, 49, p<0.0001) in the ITT analysis. Vaccine efficacy against the very severe rotavirus cases (VSRVGE, Vesikari score≥16) was 60.5% (95% CI 17.7, 81, p=0.0131) at the time of the primary analysis and 54.7% (95% CI 29.7, 70.8, p=0.0004) for the complete follow-period in the PP population. The incidence of solicited, unsolicited, and serious adverse events were similar in both the vaccine and placebo groups. Likewise, the number of intussusceptions and deaths were similar between both groups. Thus, BRV-PV is an effective, well tolerated and safe vaccine in Indian infants. (Trial registration: Clinical Trials.Gov [NCT 02133690] and Clinical Trial Registry of India [CTRI/2013/05/003667])." @default.
• W2760380650 created "2017-10-06" @default.
• W2760380650 creator A5003321077 @default.
• W2760380650 creator A5005436962 @default.
• W2760380650 creator A5006087744 @default.
• W2760380650 creator A5009697241 @default.
• W2760380650 creator A5010718673 @default.
• W2760380650 creator A5013252403 @default.
• W2760380650 creator A5014015333 @default.
• W2760380650 creator A5015076763 @default.
• W2760380650 creator A5016180624 @default.
• W2760380650 creator A5019094179 @default.
• W2760380650 creator A5019231629 @default.
• W2760380650 creator A5019332708 @default.
• W2760380650 creator A5019766599 @default.
• W2760380650 creator A5021551803 @default.
• W2760380650 creator A5023252020 @default.
• W2760380650 creator A5024819079 @default.
• W2760380650 creator A5026137282 @default.
• W2760380650 creator A5027853768 @default.
• W2760380650 creator A5028329752 @default.
• W2760380650 creator A5030329705 @default.
• W2760380650 creator A5033090057 @default.
• W2760380650 creator A5034039076 @default.
• W2760380650 creator A5035215048 @default.
• W2760380650 creator A5037320159 @default.
• W2760380650 creator A5038962061 @default.
• W2760380650 creator A5041004054 @default.
• W2760380650 creator A5044182110 @default.
• W2760380650 creator A5045948382 @default.
• W2760380650 creator A5047138862 @default.
• W2760380650 creator A5047176291 @default.
• W2760380650 creator A5048215492 @default.
• W2760380650 creator A5051922947 @default.
• W2760380650 creator A5054143122 @default.
• W2760380650 creator A5055179202 @default.
• W2760380650 creator A5057168573 @default.
• W2760380650 creator A5062812518 @default.
• W2760380650 creator A5064293656 @default.
• W2760380650 creator A5065566453 @default.
• W2760380650 creator A5067593112 @default.
• W2760380650 creator A5068620258 @default.
• W2760380650 creator A5073387169 @default.
• W2760380650 creator A5073824300 @default.
• W2760380650 creator A5075918993 @default.
• W2760380650 creator A5075987933 @default.
• W2760380650 creator A5076130506 @default.
• W2760380650 creator A5076192745 @default.
• W2760380650 creator A5083600032 @default.
• W2760380650 creator A5087299636 @default.
• W2760380650 date "2017-10-01" @default.
• W2760380650 modified "2023-10-02" @default.
• W2760380650 title "A randomized Phase III clinical trial to assess the efficacy of a bovine-human reassortant pentavalent rotavirus vaccine in Indian infants" @default.
• W2760380650 cites W1586723070 @default.
• W2760380650 cites W1812581977 @default.
• W2760380650 cites W1964571060 @default.
• W2760380650 cites W1966417805 @default.
• W2760380650 cites W1968929160 @default.
• W2760380650 cites W1976924391 @default.
• W2760380650 cites W1980712622 @default.
• W2760380650 cites W1995729833 @default.
• W2760380650 cites W1998494449 @default.
• W2760380650 cites W1998893743 @default.
• W2760380650 cites W2018388933 @default.
• W2760380650 cites W2023350150 @default.
• W2760380650 cites W2023371775 @default.
• W2760380650 cites W2024341431 @default.
• W2760380650 cites W2041651322 @default.
• W2760380650 cites W2052205735 @default.
• W2760380650 cites W2054534586 @default.
• W2760380650 cites W2057022620 @default.
• W2760380650 cites W2092090915 @default.
• W2760380650 cites W2101380815 @default.
• W2760380650 cites W2102009564 @default.
• W2760380650 cites W2111628987 @default.
• W2760380650 cites W2113014022 @default.
• W2760380650 cites W2135985984 @default.
• W2760380650 cites W2143233237 @default.
• W2760380650 cites W2144610891 @default.
• W2760380650 cites W2153883091 @default.
• W2760380650 cites W2296841462 @default.
• W2760380650 cites W2328134362 @default.
• W2760380650 cites W2416791813 @default.
• W2760380650 cites W2601776853 @default.
• W2760380650 cites W2606673236 @default.
• W2760380650 cites W4231603137 @default.
• W2760380650 cites W66439614 @default.
• W2760380650 doi "https://doi.org/10.1016/j.vaccine.2017.09.014" @default.
• W2760380650 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5651219" @default.
• W2760380650 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28967523" @default.
• W2760380650 hasPublicationYear "2017" @default.
• W2760380650 type Work @default.
• W2760380650 sameAs 2760380650 @default.
• W2760380650 citedByCount "83" @default.
• W2760380650 countsByYear W27603806502017 @default.
• W2760380650 countsByYear W27603806502018 @default.
• W2760380650 countsByYear W27603806502019 @default.
• W2760380650 countsByYear W27603806502020 @default.

• next